{"id":31275,"date":"2025-12-15T11:09:40","date_gmt":"2025-12-15T10:09:40","guid":{"rendered":"https:\/\/www.transgene.com\/?p=31275"},"modified":"2026-03-23T16:48:56","modified_gmt":"2026-03-23T15:48:56","slug":"tg6050","status":"publish","type":"post","link":"https:\/\/www.transgene.com\/fr\/tg6050\/","title":{"rendered":"produits : TG6050"},"content":{"rendered":"\n<div id=\"tetContainer\" class=\"wp-block-uagb-container uagb-block-ec6f09b8 alignfull uagb-is-root-container\">\n<div class=\"bgImg-01 wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"tgTetContainer\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\" id=\"degHaut\">\n<div class=\"wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\" id=\"degbas\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\" id=\"ongletBas\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div id=\"cont1200\" class=\"wp-block-uagb-container uagb-block-9581dd7e alignfull uagb-is-root-container\"><div class=\"uagb-container-inner-blocks-wrap\">\n<div class=\"maxWidth wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<div id=\"tgProduitIntro\">&nbsp;<\/div>\n<div id=\"titleTG\">\n<h1>TG6050<\/h1>\n<div id=\"myvacLogo\"><img decoding=\"async\" class=\"alignnone size-full wp-image-35801\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/invirio-Q2.svg\" alt=\"\"><\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<div id=\"ProduitIntro\" class=\"maxWidthTxt\">\n<h2><strong>TG6050<\/strong> est un <strong>virus oncolytique innovant<\/strong> de la plateforme Invir.IO<sup>\u00ae<\/sup>.<\/h2>\n<h2>TG6050 a \u00e9t\u00e9 con\u00e7u pour <strong>exprimer directement dans la tumeur<\/strong> de l\u2019IL-12 et un anticorps anti-CTLA4, capables d\u2019induire de <strong>fortes r\u00e9ponses immunitaires antitumorales<\/strong>.<\/h2>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"relanceContainer eplus-Hznsb4 eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-n4sHS9 eplus-wrapper wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"eplus-6DgPNw eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-EH3sBp eplus-wrapper TGrelance wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"BG-dna\">\n<h2 class=\"eplus-ATU6ZX eplus-wrapper\" style=\"color: white;\">Multiplication sp\u00e9cifique et lyse des cellules tumorales (ou oncolyse).<\/h2>\n&nbsp;<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"maxWidth wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"RubTitle rubArticle\">\n<div class=\"HpNews-container\">\n<div class=\"HpNews-content \"><a class=\"btnVideo\" title=\"\" href=\"https:\/\/vimeo.com\/786294781?width=640&amp;height=480\" rel=\"wp-video-lightbox\">D\u00e9couvrez comment fonctionne TG6050 (vid\u00e9o)<\/a>\n<div class=\"asterix astMar\">* cookies analytiques requis<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"mobilMargin wp-block-column eplus-wrapper is-layout-flow wp-block-column-is-layout-flow\">\n<p>D\u00e9riv\u00e9s de la <b>plateforme Invir.IO<\/b><sup><b>\u00ae<\/b><\/sup>, nos virus oncolytiques&nbsp;<b>infectent, se multiplient de mani\u00e8re sp\u00e9cifique et induisent la lyse des cellules tumorales&nbsp;<\/b>(ou oncolyse).<\/p>\n<p>&nbsp;<\/p>\n<p>Ces virus int\u00e8grent \u00e9galement des armes anticanc\u00e9reuses dans leur g\u00e9nome, ce qui leur permet de <b>moduler le microenvironnement tumoral<\/b>.<\/p>\n<p>&nbsp;<\/p>\n<p>Ces diff\u00e9rents m\u00e9canismes conduisent \u00e0 la destruction des cellules tumorales et \u00e0 l\u2019activation du syst\u00e8me immunitaire, tout en <b>pr\u00e9servant les cellules saines du patient<\/b>.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"relanceContainer eplus-Hznsb4 eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-n4sHS9 eplus-wrapper wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"eplus-6DgPNw eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-EH3sBp eplus-wrapper TGrelance wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"BG-dna\">\n<h2 class=\"eplus-ATU6ZX eplus-wrapper\" style=\"color: white;\">Con\u00e7u pour induire une r\u00e9ponse immunitaire forte contre la tumeur<\/h2>\n&nbsp;<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<p class=\"maxWidth eplus-wrapper wp-block-paragraph\"><\/p>\n\n\n\n<div class=\"relanceContainer eplus-Hznsb4 eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-n4sHS9 eplus-wrapper wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"eplus-6DgPNw eplus-wrapper wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-EH3sBp eplus-wrapper TGrelance wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"BG-dna\">\n<h2 class=\"eplus-ATU6ZX eplus-wrapper\" style=\"color: white;\">Derniers r\u00e9sultats disponibles<\/h2>\n&nbsp;<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"maxWidth wp-block-columns eplus-wrapper is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"eplus-EH3sBp eplus-wrapper  wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"RubTitle rubArticle\">\n<div class=\"HpNews-container\">\n<h2>Derni\u00e8res publications<\/h2>\n<div id=\"ancre-publi\" class=\" eplus-wrapper\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\"> <ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/static1.squarespace.com\/static\/56dee71e555986fb3ae583e2\/t\/66db4e7cb9451f7aac7fcd10\/1725648512282\/CICON24+Abstracts+FINAL+090524+v4.pdf\" title=\"TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment\"><div class='catlistdate'>10 septembre 2024<\/div>  <div class='catlistTitle'>TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/jitc.bmj.com\/content\/jitc\/12\/7\/e009302.full.pdf\" title=\"TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment\"><div class='catlistdate'>27 ao\u00fbt 2024<\/div>  <div class='catlistTitle'>TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/Transgene_AACR2023_TG6050_TME_remodeling_poster.pdf\" title=\"TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses\"><div class='catlistdate'>16 avril 2023<\/div>  <div class='catlistTitle'>TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses<\/div><\/a><\/li><\/ul><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"eplus-EH3sBp eplus-wrapper  wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<div class=\"RubTitle rubArticle\">\n<div class=\"HpNews-container\">\n<h2>Derniers communiqu\u00e9s de presse<\/h2>\n<div id=\"ancre-cp\" class=\" eplus-wrapper\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-36965\" style=\"max-width: 50px; margin: 20px 0 0 20px;\" src=\"https:\/\/www.transgene.com\/wp-content\/uploads\/scroll.jpg\" alt=\"\" width=\"145\" height=\"143\" \/> <ul class=\"lcp_catlist\" id=\"lcp_instance_0\"><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250206_TRANSGENE_Eligibilite-PEA-PME_FR.pdf\" title=\"L&rsquo;action Transgene (Euronext Paris : TNG) \u00e9ligible au dispositif du PEA-PME\"><div class='catlistdate'>6 f\u00e9vrier 2025<\/div>  <div class='catlistTitle'>L&rsquo;action Transgene (Euronext Paris : TNG) \u00e9ligible au dispositif du PEA-PME<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250121_Transgene_Prochains-RDV-Investisseurs_FR.pdf\" title=\"Transgene participera \u00e0 la conf\u00e9rence investisseurs Biomed Forum\"><div class='catlistdate'>21 janvier 2025<\/div>  <div class='catlistTitle'>Transgene participera \u00e0 la conf\u00e9rence investisseurs Biomed Forum<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20250114_TRANSGENE_Agenda_Financier_2025_FR.pdf\" title=\"Transgene pr\u00e9sente son calendrier de communication financi\u00e8re pour 2025\"><div class='catlistdate'>14 janvier 2025<\/div>  <div class='catlistTitle'>Transgene pr\u00e9sente son calendrier de communication financi\u00e8re pour 2025<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20240827_TRANSGENE_TG6050-JITC-FR.pdf\" title=\"Transgene publie dans le JITC des donn\u00e9es de preuve de concept pr\u00e9clinique du virus oncolytique TG6050\"><div class='catlistdate'>27 ao\u00fbt 2024<\/div>  <div class='catlistTitle'>Transgene publie dans le JITC des donn\u00e9es de preuve de concept pr\u00e9clinique du virus oncolytique TG6050<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20230510_Transgene_TG6050_Delivir_trial_FPI_FR.pdf\" title=\"Transgene &#8211; Premier patient trait\u00e9 dans l&rsquo;essai de Phase I \u00e9valuant TG6050, un virus oncolytique innovant arm\u00e9 avec de l&rsquo;IL-12, dans le cancer du poumon non \u00e0 petites cellules\"><div class='catlistdate'>10 mai 2023<\/div>  <div class='catlistTitle'>Transgene &#8211; Premier patient trait\u00e9 dans l&rsquo;essai de Phase I \u00e9valuant TG6050, un virus oncolytique innovant arm\u00e9 avec de l&rsquo;IL-12, dans le cancer du poumon non \u00e0 petites cellules<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20230417_Transgene_AACR_TG6050_FR.pdf\" title=\"Pr\u00e9sentation \u00e0 l&rsquo;AACR de r\u00e9sultats pr\u00e9cliniques montrant que TG6050, un virus oncolytique innovant, induit une r\u00e9gression tumorale gr\u00e2ce \u00e0 l&rsquo;activation des r\u00e9ponses immunitaires inn\u00e9es et adaptatives\"><div class='catlistdate'>17 avril 2023<\/div>  <div class='catlistTitle'>Pr\u00e9sentation \u00e0 l&rsquo;AACR de r\u00e9sultats pr\u00e9cliniques montrant que TG6050, un virus oncolytique innovant, induit une r\u00e9gression tumorale gr\u00e2ce \u00e0 l&rsquo;activation des r\u00e9ponses immunitaires inn\u00e9es et adaptatives<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/wp-content\/uploads\/20230315_-_AACR_Curtain_raiser_FR.pdf\" title=\"Transgene pr\u00e9sentera plusieurs posters soulignant le potentiel de son portefeuille d&rsquo;immunoth\u00e9rapies \u00e0 l&rsquo;AACR 2023\"><div class='catlistdate'>15 mars 2023<\/div>  <div class='catlistTitle'>Transgene pr\u00e9sentera plusieurs posters soulignant le potentiel de son portefeuille d&rsquo;immunoth\u00e9rapies \u00e0 l&rsquo;AACR 2023<\/div><\/a><\/li><li><a class=\"count\" onclick=\"count()\" href=\"https:\/\/www.transgene.com\/CP.php?f=31245&amp;link=20230106_Transgene_TG6050_Delivir_ANSM_FR.pdf\" title=\"Transgene re\u00e7oit l&rsquo;autorisation de lancer un essai de Phase I avec TG6050, un virus oncolytique innovant arm\u00e9 avec de l&rsquo;IL-12 et administr\u00e9 par voie intraveineuse\"><div class='catlistdate'>6 janvier 2023<\/div>  <div class='catlistTitle'>Transgene re\u00e7oit l&rsquo;autorisation de lancer un essai de Phase I avec TG6050, un virus oncolytique innovant arm\u00e9 avec de l&rsquo;IL-12 et administr\u00e9 par voie intraveineuse<\/div><\/a><\/li><\/ul><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; TG6050 TG6050 est un virus oncolytique innovant de la plateforme Invir.IO\u00ae. TG6050 a \u00e9t\u00e9 con\u00e7u pour exprimer directement dans la tumeur de l\u2019IL-12 et un anticorps anti-CTLA4, capables d\u2019induire de fortes r\u00e9ponses immunitaires antitumorales. &nbsp; Multiplication sp\u00e9cifique et lyse des cellules tumorales (ou oncolyse). &nbsp; D\u00e9couvrez comment fonctionne TG6050 (vid\u00e9o) * cookies analytiques requis&hellip; <a class=\"more-link\" href=\"https:\/\/www.transgene.com\/fr\/tg6050\/\">Poursuivre la lecture <span class=\"screen-reader-text\">produits : TG6050<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_uag_custom_page_level_css":"","footnotes":""},"categories":[110],"tags":[],"class_list":["post-31275","post","type-post","status-publish","format-standard","hentry","category-outils-produits","entry"],"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false},"uagb_author_info":{"display_name":"alcyon","author_link":"https:\/\/www.transgene.com\/fr\/author\/alcyon\/"},"uagb_comment_info":0,"uagb_excerpt":"&nbsp; TG6050 TG6050 est un virus oncolytique innovant de la plateforme Invir.IO\u00ae. TG6050 a \u00e9t\u00e9 con\u00e7u pour exprimer directement dans la tumeur de l\u2019IL-12 et un anticorps anti-CTLA4, capables d\u2019induire de fortes r\u00e9ponses immunitaires antitumorales. &nbsp; Multiplication sp\u00e9cifique et lyse des cellules tumorales (ou oncolyse). &nbsp; D\u00e9couvrez comment fonctionne TG6050 (vid\u00e9o) * cookies analytiques requis&hellip;\u2026","_links":{"self":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/31275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/comments?post=31275"}],"version-history":[{"count":12,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/31275\/revisions"}],"predecessor-version":[{"id":40691,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/posts\/31275\/revisions\/40691"}],"wp:attachment":[{"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/media?parent=31275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/categories?post=31275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.transgene.com\/fr\/wp-json\/wp\/v2\/tags?post=31275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}